Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban Dose-Ranging Study for VTE Prevention in Hip Replacement
NCT00398905Phase 2Completed
- Sponsor
- Bayer
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of rivaroxaban in venous thromboembolism (VTE), sponsored by Bayer. Started Jan 2004; status: completed.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00398905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00398905.